11:32:34 PM

EVOTF Stock News

EVOTF - Evotec SE

01/11/22 2:00 AM

OTC, Nasdaq : EVOTF, EVO

Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach

January 11,

RHEA-AI

neutral

01/03/22 1:55 AM

OTC, Nasdaq : EVOTF, EVO

covid-19

Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic

EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OF

RHEA-AI

positive

EVOTF Data:

IndustryPharmaceuticals: Major
Websitehttp://evotec.com
CeoWerner Lanthaler
Security nameEvotec SE
Issue typecs
SectorHealth Technology
Sic code2834
Tags
- Biotechnology
- Health Technology
- Pharmaceuticals: Major
AddressManfred Eigen Campus
CityHamburg
Zip22419
CountryDE
Phone49.40.56081.0

EVOTF Description:

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.